Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × ER+ Breast Cancer × Fulvestrant × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 132 Neoplasm Metastasis 15 Advanced Breast Cancer 8 Ovarian Neoplasms 7 Prostatic Neoplasms 5 Neoplasms 5 Breast Cancer Metastatic 5 Endometrial Neoplasms 4 Recurrence 3 Hereditary Sensory and Autonomic Neuropathies 3 Carcinoma, Non-Small-Cell Lung 3 Lung Neoplasms 2 Hyperglycemia 2 Exanthema 2 Estrogen Receptor-positive Breast Cancer 2 Breast Neoplasms, Male 2 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Sex Cord-Gonadal Stromal Tumors 1 Sarcoma, Endometrial Stromal 1 Salivary Gland Neoplasms 1 Recurrent Uterine Corpus Carcinoma 1 Pancreatic Neoplasms 1 Neoplastic Cells, Circulating 1 Multiple Endocrine Neoplasia Type 1 1 Melanoma 1 Malignant Neoplasms of Female Genital Organs 1 Locoregional Recurrence 1 Liposarcoma 1 Lethal Congenital Contracture Syndrome 2 1

Interventions

palbociclib 1 exemestane 1 elacestrant 1 Tamoxifen 1 Letrozole 1 Fulvestrant 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04985266 2024-12-05

TRAK-ER

Royal Marsden NHS Foundation Trust

Phase 2 Recruiting

ER+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡